Severe hypertensive patients with uncontrolled hypertension
Conditions
Interventions
Continuous oral administration of amlodipine (5-7.5mg/day)
Switch to oral administration of telmisartan (40-80mg/day)+low-dose hydrochrolthiazide (12.5mg/day) combination therapy
Sponsors
Non profit Organization LINE
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hypertensive patients (office systolic blood pressure over 140 mmHg and/or office diastolic blood pressure over 90 mmHg) with oral administration of amlodipine (5mg/day)
Exclusion criteria
Exclusion criteria: 1) Endocrine hypertension 2) Severe hypertension with office systolic blood pressure over 180mmHg and/or diastolic blood pressure over 90mmHg 3) Malignant hypertension 4) Continuous ventricular tachycardia or severe arrythmia (AV block II-III, Af etc) 5) Severe heart failure (NYHA III-IV) 6) Myocardial Infarction, Coronary bypass surgery, and Intervention therapy were performed within 6 months 7) Patients with exclusion criteria of amlodipine, telmisartan and hedrochrolthiazide 8) Serum creatinine >2.1mg/dl 9) Serum potassium >5.5mEq/l or <3.5mEq/l 10) Untreated hyperuricemia or treated hyperuricemia with UA>8.0mg/dl 11) ACEI, ARB and Diuretic treated patients 12) Uncontrolled diabetic patients (HbA1c>9.0%) and diabetic patients with insulin injection 13) Hypoglycemia 14) Hypersensitivity with telmisartan and hydrochrolthiazide 15) Patients who are inadequate to entry this study by physicians in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of morning and evening home blood pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in office blood pressure, uric acid, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, fast blood glucose and HbA1c | — |
Countries
Japan
Contacts
Public ContactHidetomo Nakamoto
Saitama Medical University Department of General Medicine
Outcome results
None listed